Spotlight on Science Meetings, Conferences and Events brings you information on the following event: 2nd Annual Liquid Biopsy Summit
This is an unprecedented time in biomolecular medicine. 1) Recent scientific findings have determined biofluids consist of circulating tumor cells (CTCs), cell-free nucleic acid (cfNA), or extracellular vesicles from multiple tissues within the body. 2) Rapid development of highly sensitive and accurate next-generation sequencing (NGS) technologies has allowed analysis of the role of these biomolecules, and has been rapidly adopted into molecular diagnostic laboratories. And 3) researchers are empowered to analyze the role of these biomolecules in health, disease and treatment response leading to targeted therapies. However, there still remains insecurity associated with biofluid-based DNA/RNA analytical methods, which must be solved before liquid biopsies can be implemented for broader routine applications. At The Liquid Biopsy Summit, experts present and consider process and technology refinements that can enable molecular liquid biopsies to become a fulcrum in the future of precision medicine.
